Great question! Xolair (omalizumab) works by targeting and blocking IgE antibodies — the immune system proteins responsible for triggering allergic reactions to foods like peanuts, milk, eggs, tree nuts, wheat, and shellfish.
Here's what's currently known about Xolair:
- It was FDA-approved in February 2024 to reduce the Show Full Answer
Great question! Xolair (omalizumab) works by targeting and blocking IgE antibodies — the immune system proteins responsible for triggering allergic reactions to foods like peanuts, milk, eggs, tree nuts, wheat, and shellfish.
Here's what's currently known about Xolair:
- It was FDA-approved in February 2024 to reduce the risk of severe allergic reactions from food allergens
- It does not cure food allergies or prevent new ones from developing
- It is not designed to treat anaphylaxis once it occurs
- It can rarely *cause* anaphylaxis as a side effect
- It is given as an injection under the skin every two to four weeks Since alpha-gal syndrome involves a different immune pathway (not IgE-driven in the same way), Xolair is not considered a treatment for it. Xolair specifically targets IgE antibodies, so its benefits are limited to IgE-mediated allergies.
There is currently no evidence that Xolair prevents *new* food allergies from forming. It manages existing sensitivity rather than reshaping the immune system's future responses.
Talking with an allergist is the best way to find out if Xolair is a good fit for a specific allergy profile.
May 31
Join
Your Privacy Choices
